[PDF][PDF] Ovarian cancer treatment with a liposome formulated mRNA vaccine in combination with (neo-) adjuvant chemotherapy: Study protocol of the OLIVIA phase I …
ST Paijens, AKL Reyners, M de Bruyn… - Tumor immunology and … - research.rug.nl
Advanced stage epithelial ovarian cancer (EOC) is the leading cause of death from
gynaecological malignancies with a 5-year survival of no more than 40%. Current treatment …
gynaecological malignancies with a 5-year survival of no more than 40%. Current treatment …
[引用][C] A SOCS1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human monocyte-derived …
Y Wang, S Wang, Y Ding, Y Ye, Y Xu… - Clinical and Vaccine …, 2013 - Am Soc Microbiol
[引用][C] A SOCS1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human 2 monocyte-derived …
Q Li, Y Mi, C Guo, Z Lin, T Liu, Y Zhang, Y Chen, J Yan - 2013 - Am Soc Microbiol
[引用][C] RNA Vaccines in Cancer Treatment
B Anita, H Stefanie Andrea Erika… - … of Biomedicine and … - Hindawi Publishing Corporation